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Abstract

SILDENAFIL AND CELECOXIB INTERACT TO KILL BREAST CANCER CELLS
By Brittany Binion, MS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2014
Major Director: Paul Dent, Ph.D. Department of Biochemistry
Breast cancer is the second most commonly diagnosed cancer among American women
and is responsible for the second highest number of cancer-related deaths. Targeted therapeutic
agents sildenafil, a phosphodiesterase type 5 inhibitor, and celecoxib, a cyclooxygenase-2
inhibitor, have been used individually in conjunction with other chemotherapeutic agents to
enhance cell killing in a variety of cancers. Sildenafil when combined with traditional
chemotherapeutic drugs, such as the taxanes and anthracyclines, or celecoxib combined with
traditional hormone therapies have been used to increase cytotoxicity and cell killing. The data
presented here demonstrates that the novel combination of sildenafil and celecoxib work together
to enhance cell killing in both receptor positive and triple negative breast cancer through the
induction of autophagy, ER stress, as well as both intrinsic and extrinsic apoptosis.

Introduction
Breast Cancer
Over 200,000 new cases of invasive breast cancer are diagnosed in the United States each
year, and approximately 40,000 of the patients diagnosed will die from the disease.1 From 2001
to 2010, the incidence of breast cancer in the United States remained level among women, and
the mortality rate decreased by 2.0% per year2. It has been suggested that at least half of the
reduction in breast cancer mortality that was observed over the last thirty years is attributable to
the widespread use of adjuvant therapy.3 It is common to classify the disease based upon nodal
status, tumor grade and size, as well as other prognostic factors such as hormone receptor
status.4,5 These designations are useful, particularly the expression of receptors present in the
cancer, as they are used to determine potentially effective treatments.
The breast cell lines utilized in experiments in this manuscript were ductal carcinomas,
with differing receptor expression patterns, indicated in table 1. The BT 474 cell line is
characterized mostly by the overexpression of human epidermal growth factor receptor 2
(HER2), as it retains functional estrogen receptors (ER) and progesterone receptors (PR).6,7
However, the BT 549 cell line is referred to as triple negative breast cancer (TNBC), as it does
not express any of the three major receptors used in breast cancer diagnosis.8 The absence of ER
and PR expression has been shown to be associated with early disease recurrence and poor
survival, and 15% of breast cancers diagnosed worldwide are designated as TNBC .1, 9, 10, 11, 12
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Table 1: Cell line receptor expression. A table listing the characteristic receptor expression
status of the cell lines used in this study. For expression levels, (-) signifies absent, (+) indicates
expression, (++) signifies overexpression.
Cell line

ER

PR

HER2

BT 474

+

+

++

BT 549

-

-

-

Conventional Treatment
The conventional treatment course for patients with breast cancer typically involve
surgical removal and a neo-adjuvant (pre-surgery) or more commonly an adjuvant (post-surgery)
therapy. These adjuvant therapies can include radiation, chemotherapeutics such as
anthracyclines and taxanes, hormone therapy, targeted therapy, or a combination of treatments.
TNBC is highly aggressive, and is responsible for a disproportionate number of
metastatic disease cases and breast cancer deaths.13,14,15 It is typically treated with a combination
of cytotoxic chemotherapy agents, including the anthracyclines and taxanes.16 Commonly there
is residual disease after treatment of early breast cancer, and these patients have a high risk of
relapse, with a sharp decrease in survival in the first 3 to 5 years after treatment.13, 17, 18, 19
Conventional treatments for relapsed patients are limited, particularly because standard
chemotherapeutic regimens containing anthracyclines and taxanes have already been given in the
adjuvant and neoadjuvant settings, opening up the potential for resistance to drugs already
administered.20
Typically, conventional chemotherapy does not have the ability to discriminate between
normal rapidly dividing cells and cancer cells and has low therapeutic efficacy. In contrast,
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targeted therapies have specific molecular targets in tumor cells, which act with higher
specificity and induce less overall toxicity.21 Due to these aspects of targeted therapies, they
represent a more promising approach based on the molecular understanding of tumorigenesis,
which may potentially replace conventional cytotoxic chemotherapy in the future. The largest
obstacle in targeted therapies comes from the potential for crosstalk between cellular survival
pathways, commonly resulting in the activation of alternative pathways, ultimately leading to
drug resistance. Therefore, it is becoming more evident that targeted therapeutics used in
combination may provide a more rational strategy to increase the efficacy of drug treatments in
cancer patients.
Hormone and Targeted Therapies
Both the ER and the PR play important roles in the physiology of the reproductive tract,
and have effects on the normal growth of the breast as well as the progression of breast cancer.22,
23

The ER is a hormone-regulated nuclear transcription factor that can induce the expression of a

number of genes, including that of the PR.24 Upon ligand activation, ER binds to estrogen
response elements on target genes and regulates the transcription of these specific genes,
including that of the PR.25 Due to the complex nature of co-regulatory proteins and extra nuclear
actions involved in ER signaling, there is a requirement for tight regulation of these factors, with
dysregulation being implicated in the progression of cancer attributed to the importance of ER in
growth and survival pathways.23 For hormone receptor positive patients, therapeutic strategies
are commonly directed at inhibiting the actions of ER using selective ER modulators (SERMs),
targeting ER for degradation with selective ER downregulators (SERDs), or withdrawing
estrogen via surgical methods (oophorectomy) or medically by aromatase inhibitors in postmenopausal women.26
3

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase gene that
is amplified and causes overexpression of protein in 20-30% of metastatic breast cancer.27 This
amplification and overexpression is associated with reduced time to progression of the disease as
well as a reduction in overall survival in breast cancer patients.28 The HER2 gene does not need
to be mutated for oncogenic function, simply the amplification of wild-type HER2 is sufficient to
produce the oncogenic effects.
In HER2 overexpressing cells, excess expression can lead to spontaneous and constitutive
ligand-independent dimerization, which activates the cytoplasmic kinase region of the
receptor.29, 30, 31 This kinase activation can stimulate autophosphorylation of tyrosine residues
within the cytoplasmic domain of the receptors and initiate downstream signaling, primarily
though the AKT and MAPK pathways, ultimately leading to increased proliferation, protein
synthesis and cell survival.27 The PI3K/AKT signaling pathway is a major effector of HER2
activity; PI3K blockade suppressed tumor growth in multiple models of HER2-overexpressing
breast cancers.32, 33 MAPK signaling appears to contribute to progression of HER2-positive
breast cancer, with hyper activation of MAPK signaling and resistance to the ER modulator
tamoxifen seen in HER2 and ER-positive cells.31
Post-surgery, adjuvant treatments for HER2-positive breast cancer patients typically
involves long-term treatment with trastuzumab (Herceptin), a monoclonal antibody that attaches
to HER2 receptors on breast cancer cells and blocks them from receiving growth signals. This
blockade can slow or even stop cancer growth. In the event that the cancer metastasizes, a
tyrosine kinase inhibitor called lapatinib is used to inhibit receptor signal processes by binding to
the ATP-binding pocket of the HER2 protein kinase domain.35 This prevents
autophosphorylation and subsequent activation of downstream signaling mechanisms.
4

Taken together, most common therapies are geared towards directly blocking or
eliminating receptor activation. However, there is evidence of crosstalk between ER, PR and
growth factor receptor signaling pathways, especially the epidermal growth factor receptor
(EGFR) family, as one of the mechanisms for resistance to endocrine therapy in breast cancer.36,
37, 38

Bidirectional crosstalk between ER and growth factor pathways, particularly HER2, result

in a positive feedback cycle of survival and cell proliferative stimuli.38 This indicates that the
current methods of blocking receptor signaling are no longer as effective, as resistances are
becoming more commonplace. Drug resistance is also of particular concern for TNBC patients as
therapies are quite limited for patients experiencing cases of metastasis. This is largely due to a
lack of targeted therapies available as well as the prevalence for acquired resistance against
chemotherapies previously administered.
Sildenafil
Phosphodiesterases (PDEs) are a family of enzymes which catalyze the hydrolysis of the
cyclic nucleotides to their corresponding 5-monophosphate counterparts, leading to a decrease in
levels of the cyclic nucleotides.39 Sildenafil (Viagra) is an oral PDE inhibitor specific to isoform
5 (PDE5), with selectivity for cyclic guanosine monophosphate (cGMP).40, 41 Nitric oxide (NO)
stimulates the enzyme guanylate cyclase to convert guanosine triphosphate (GTP) to cGMP, with
high levels of cGMP being responsible for the relaxation of smooth muscle.42 Thus, sildenafil
enhances the actions of the endogenous NO-cGMP pathway, by mediating the elevation of
cGMP levels due to inhibiting its degradation by PDE5.43, 44 Due to the localization of PDE5 in
the corpus cavernosum, sildenafil is successfully used in the treatment of erectile dysfunction.
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It has been demonstrated that hypoxia-induced inhibition of intracellular NO-cGMP
signaling can lead to a more malignant phenotype in cancer cells, including chemoresistance and
evasion of immune detection.45, 46 PDE-specific inhibition decreased hypoxia-mediated chemo
resistance, confirming the potential clinical utilization of enhancing NO-cGMP signaling to
chemo sensitizes cancer cells.45,46, 47 Thus, PDE5 inhibitors may be used as an anticancer therapy,
due to their essential role in regulating cGMP, which as a second messenger causes a reduction
in cell growth as well as the induction of apoptosis.48, 49, 50
It has also been demonstrated that when paired with standard of care chemotherapy
treatments, such as doxorubicin, sildenafil mediates a cardio protective effect through the NOcGMP pathway involving the enhanced expression of nitric oxide synthase (NOS).51 This
protective effect offsets one of the biggest concerns with doxorubicin treatment as well as
enhancing doxorubicin induced cell death through apoptosis, particularly the extrinsic pathway
through death receptors.51, 52
Sildenafil is generally administered as a single 50 milligram (mg) dose per day as needed,
and can be adjusted up to 100 mg or down to 25 mg. It is well tolerated by patients, with the
occurrence of mild side effects such as headache, flushing, dyspepsia, nasal congestion, urinary
tract infection, abnormal vision, diarrhea, dizziness, and rash.
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Figure 1: Chemical structure of sildenafil72
Celecoxib
Celecoxib (Celebrex) was the first specific inhibitor of cyclooxygenase-2 (Cox-2)
approved by the US Food and Drug Administration (FDA) in December of 1998 to treat patients
with rheumatoid arthritis and osteoarthritis.53 The purpose of Celecoxib was to produce a nonsteroidal anti-inflammatory drug (NSAID) that had little to no effects on the gastrointestinal
system or the kidneys, which are commonly negatively affected by NSAIDS.
Patients taking celecoxib have an initial recommended dosage of 200mg daily for
osteoarthritis and 400 mg daily for rheumatoid arthritis.54 Common side effects are relatively
mild, and include abdominal pain, diarrhea, dyspepsia, flatulence, dizziness, upper respiratory
tract infection and rash, with a potential for increased cardiovascular risks.55
The COX enzymes catalyze the synthesis of prostaglandins (PGs) from arachidonic acid,
which are important messengers involved in the process of inflammation.56 There are two
7

isoforms of COX, with COX-1 being expressed in most tissues and producing PGs that are
responsible for the control of normal physiological functions such as the maintenance of gastric
mucosa.56 Thus the gastric side effects caused by traditional NSAIDs that non-selectively inhibit
both isoforms of COX are likely through the inhibition of COX-1, which mediates
gastroprotective PGs. In contrast, COX-2 is not found in most normal tissues and is induced by
inflammatory stimuli, which leads to enhanced synthesis of PGs in neoplastic and inflamed
tissues.56 The selectivity of COX inhibitors arises from a single substitution in the NSAID
binding site, which produces a void volume to the side of the central active-site channel;
compounds that bind in this additional space inhibit COX-2 selectively.57
It was noted that long term use of NSAIDs appeared to reduce the risk of developing
cancer.56, 58 COX2 is commonly observed to be upregulated in cancer, including breast, and
administration of celecoxib caused a greater suppression of the incidence of malignant breast
tumors when compared to the administration of traditional NSAIDs.59, 60 It was indicated that the
increase in tumorigenic potential by COX2 overexpression was associated with a resistance to
apoptosis through the overproduction of PGs, and celecoxib was therefore inducing apoptosis.61
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Figure 2: Chemical structure of celecoxib.73
Apoptosis: Intrinsic and Extrinsic Pathways
Apoptosis is a form of programmed cell death that is intimately involved in the
development and homeostasis of normal tissues.62 Most notably, apoptosis is characterized by
morphological changes that take place, such as cell shrinkage, membrane blebbing, nucleus
fragmentation, chromatin condensation and DNA degradation.63, 64, 65 Within the designation of
apoptosis there are two distinct pathways: the extrinsic, or death receptor pathway, and the
intrinsic, or mitochondrial pathway (figure 3). It is suggested that these two pathways are
connected, and have the ability influence each other.63 Both the intrinsic and extrinsic pathways
ultimately converge on the activation of specific intracellular proteases, known as the caspase
family, that are responsible for cleaving proteins adjacent to aspartate residues. These proteases
are commonly categorized as initiators or executioners and are synthesized as inactive zymogens
that become activated through cleavage by their upstream modulators.63, 66 Caspase 3 is the most
9

important executioner, as it is the link between the two pathways; it is activated by any of the
initiator caspases (8, 9 and 10). Executioner caspases (3, 6 and 7) cleave and affect a multitude of
substrates, including cytoskeletal and nuclear proteins, as well as activating other proteases and
endonucleases involved in protein degradation and DNA fragmentation.63,66
The intrinsic pathway is strictly regulated by the B-cell lymphoma-2 (Bcl-2) family of
proteins.63, 66 This family contains three different classes of proteins: the anti-apoptotic group I,
the pro-apoptotic group II, and group III proteins that are responsible for binding and regulating
the activity of anti-apoptotic group II proteins. The group I family members such as Bcl-2, B-cell
lymphoma-extra large (Bcl-xL) and myeloid cell leukemia-1 (Mcl-1) bind directly to and inhibit
pro-apoptiotic group II family members, that include Bcl-2-associated X protein (Bax) and Bcl-2
homologous antagonist/killer (Bak). The group III family members that include p53 unregulated
modulator of apoptosis (Puma), NADPH oxidase activator (Noxa), BH3 interacting domain
death agonist (BID) and Bcl-2 interacting mediator of cell death (BIM) all interact with the
group II pro-apoptotic members as well, however they induce the insertion of the group II
proteins into the mitochondrial membrane.63, 66, 67 Recently studies have demonstrated that the
tumor suppressor p53 may be implicated in the synthesis of Puma and Noxa, providing a link
between DNA damage and apoptotic cell death.68, 69
Various stimuli, including viral infection, DNA damage and the absence of particular
growth factors such as hormones and cytokines lead to the activation of the intrinsic pathway.
Upon exposure to these stimuli, Bax and Bak are inserted in to the mitochondrial outer
membrane, leading to membrane permeabilization via the formation of pores. The formation of
these pores leads to the release of cytochrome-c and other various pro-apoptotic proteins that
include caspase-activated deoxyribonuclease (CAD), apoptosis-inducing factor (AIF) and
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endonuclease G, from the inter-membrane space in the mitochondria to the cytosol.63, 66 Once in
the cytosol, cytochrome-c binds to apoptotic protease-activating factor-1 (Apaf-1), which then
binds pro-caspase 9 to form a complex called the apoptosome that includes multiple Apaf-1 and
procaspase 9 molecules.70 The binding event induces a conformational change and leads to the
activation of caspase 9, that goes on to proteolytically activate the executioner caspase 3.63, 66
Once activated, caspase 3 goes on to activate caspase 6 as well as CAD through cleavage of its
inhibitor (ICAD).70 CAD, with AIF and endonuclease G, translocates to the nucleus where they
all contribute to DNA fragmentation.63, 65, 66
Binding of ligands from the tumor necrosis factor (TNF) family to death receptors leads
to the activation of the extrinsic pathway. These TNF family receptors consist of a cysteine-rich
extracellular domain for ligand binding and a cytoplasmic domain of 80 amino acids, termed the
death domain (DD), which is involved in transducing the signal into the cell.63, 65, 67
The best characterized member of this receptor family is the Fas receptor, also called
cluster of differentiation 96 (CD95). CD95 is a 45 kDa trans-membrane protein that upon
binding with its ligand, FasL, induces a conformational change allowing for the recruitment of an
adaptor protein called Fas-associated death domain (FADD). FADD itself contains another key
motif, the death-effector domain (DED) that binds complementary DED domains on initiator
caspases 8 and 10.63, 65, 67 This entire intracellular complex is titled the death-inducing signaling
complex (DISC) and its formation leads to the auto-proteolytic cleavage and activation of
caspases 8 and 10.The activation of these initiatior caspases then causes the activation of the
executioner caspases 3 and 7, that are responsible for the induction of the apoptotic response.63,65,
67

This pathway can be inhibited by FLICE-inhibitory proteins (FLIP), which bind to the DISC

and inhibit the activation of caspase 8.65,67 The extrinsic pathway may also cause the release of
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cytochrome-c and the induction of the intrinsic pathway through activation of BID, which serves
as a substrate for caspase 8. Upon the activation of the DISC, truncated BID (tBID) translocates
to the mitochondria and induces the release of apoptotic proteins from the inter membrane space
into the cytosol.63, 65, 71
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Figure 3: The intrinsic and extrinsic apoptotic pathways.74 The intrinsic pathway is
controlled by the Bcl-2 family of proteins that induce the release of cytochrome-c from the intermembrane space of mitochondria in to the cytosol. Cytochrome-c causes Apaf-1 to bind and
activate initiator caspase 9. Cleaved caspase 9 then activates executioner caspase 3. The extrinsic
pathway is initiated by binding of TNFs to TNFRs that recruit adaptor proteins that can bind and
activate initiator caspases 8 and 10. These initiator caspases in turn activate caspases 3 and 7.
Caspase 8 also activates BID, which can translocate to the mitochondria and induce the release
of cytochrome-c.
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Autophagy
Autophagy is another mechanism that is tasked with maintaining cellular homeostasis,
and this happens through the regular recycling and turnover of cytoplasmic components. This
process is a multifunctional pathway associated with not only the removal of damaged
organelles, but as a method of programmed cell death and various physiological and pathological
processes that include: normal development, aging, cancer, and neurodegenerative diseases.75, 76,
77, 78, 79

Where apoptosis is an irreversible form of cell death, autophagy can lead to either cell

death or, paradoxically, it can allow cells to escape death and therefore can be considered a
protective mechanism at times.80
An organelle called the lysosome contains hydrolytic enzymes that give it the ability to
degrade cellular components and whole organelles.75 The process of getting these cellular
components to the lysosome is collectively referred to as autophagy. There are three distinct
categories of autophagy: microautophagy, chaperone-mediated autophagy and macroautophagy.
Microautophagy involves the direct engulfment of cytoplasmic components by the lysosome
through an invagination of the lysosomal membrane.75, 76, 81 Cytoplasmic proteins that are to be
degraded may contain specific motifs that are recognized by lysosomal receptors, leading to
chaperone-mediated autophagy.75, 75, 81 Macroautophagy, henceforth referred to simply as
autophagy (figure 4), is the main method of turnover for cytoplasmic components, such as longlived macromolecules and organelles. The process of autophagy begins with sequestration of
cytoplasm into the isolation membrane, that goes on to become a double-membrane vesicle
called the autophagosome. The autophagosome fuses with the lysosome and at this point the
inner membrane of the autophagosome and its contents are degraded by the hydrolases present
within the lysosome.82,83
14

To elucidate the molecular mechanisms that underlie the process of autophagy,
mutagenesis-based genetic screens have been performed in yeast. These studies have revealed a
host of genes not only in yeast, but in mammals that are responsible for the regulation of the
autophagic response, termed autophagy-related genes (ATG).75, 76 It has been observed that
autophagy is a highly conserved evolutionary process and there are many homologues with
similar functionality in the mammalian system.75, 76
Three different signaling complexes and pathways are integral to the development of an
autophagic response: including the mammalian target of rapamycin (mTOR) signaling pathway,
the ATG1 complex and the class III phosphoinositide 3-kinase (PI3KC3) complex. mTOR is a
serine/threonine kinase that is responsible for sensing changes in nutrient conditions to control
multiple cellular processes. In respect to autophagy, mTOR is responsible for causing changes in
the phosphorylation of ATG13. Under nutrient-rich conditions, mTOR activation causes
hyperphosphorylation of ATG13, preventing its association with the mammalian orthologue of
ATG1 known as ULK1 (Unc51-like kinase 1).75, 77 However, under starvation conditions
mTOR’s inhibitory affects are inhibited, causing hypophosphorylation of ATG13, leading it to
interact with ULK1. Activated ULK1 is recruited by ATG14L to directly phosphorylate Beclin-1
(ATG 6) and induce activation of the PI3KC3 complex. The PI3Ks represent a family of
enzymes that are implicated in an array of diverse cellular processes, such as intracellular
trafficking, proliferation and assembly of cytoskeletal elements.84 Activated PI3KC
phosphorylates phosphoatidylinositol (PI) to produce phosphatidylinositol 3-phosphate (PI3P)
that serves as an anchor for PI3P-binding proteins, such as ATG18 to bind and form
phagophores.85 Studies show that there are two different PI3KC complexes: complex one is
involved in the formation of phagophores and includes PI3KC, p150, Beclin-1 and ATG14L
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while complex two contributes to the maturation of the autophagosome and contains UVRAG
(ultraviolet radiation resistance-associated gene) in place of ATG14L.86, 75, 76
Phagophores, also known as isolation membranes, are crescent-shaped membranes that
are extended to form double-membrane autophagosomes through a process that requires two
ubiquitin-like (UBL) conjugation systems. These systems function similarly to the ubiquitylation
process involved in protein degradation, and requires three enzymes: ubiquitin-activating
enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase enzyme (E3)
(Marino, Mizushima). In the first UBL system ATG12 is activated by an E1-like enzyme ATG7,
and forms a thioester intermediate before being transferred to ATG10, an E2-like enzyme. The
last step involves covalently linking ATG5 and ATG12, and this conjugate non-covalently
interacts with ATG16L to form the final complex. This complex dissociates from the membrane
when autophagosome formation is completed.75, 87
The second UBL system involves the modification and incorporation of microtubuleassociated protein 1 Light Chain 3 (LC3) into the autophagosome membrane. The C-terminal
region of LC3 is cleaved by ATG4 to form LC3-I and the E1-like enzyme ATG7 activates it.
Upon activation, LC3-I is transferred to ATG3, an E2-like enzyme, and finally covalently bound
to phosphatidylethanolamine (PE) to form the lipid-protein conjugate LC3-II. Upon formation,
autophagosomes are fused with lyosomes to complete the protein degradation process.75, 87
As well as having the major role of recycling macromolecules and organelles during
times of nutrient deprivation, autophagy can also take part in the degradation of misfolded
proteins. This process is mediated by the adaptor molecule p62, which has domains that bind to
both the ubiquitin moiety on poly-ubiquitinated misfolded proteins, as well as the LC3 on the
autophagosome membrane. Lysosomal degradation of autophagosomes results in a decrease in
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p62 levels, which makes p62 another suitable marker for tracking autophagy in mammalian
cells.88
Autophagy can induce two opposing responses in cancer cells: protection leading to cell
survival and cytotoxicity resulting in cell death. Although toxic effects of autophagy had been
proposed to be accompanied by apoptosis, it has been demonstrated that knockdown of the antiapoptotic protein Bcl-2 induced caspase-independent autophagic cell death, by increasing the
expression of Beclin1.89 This study ultimately suggested that autophagy can directly induce cell
death without activating apoptotic pathways.
It has been documented that there is a link between autophagy and the unfolded protein
response (UPR). Both processes are closely related as some of the signaling routes activated
during the ER stress response are involved in stimulating autophagy.90 There is indication that
the phosphorylation of eukaryotic initiation factor α (eIF2α) in the UPR is linked to the induction
of autophagy.

17

Figure 4: An overview of the autophagic pathway.91 Upon release of inhibitory effects by
mTOR, ULK1 is activated and causes the phosphorylation of Beclin1, which activates the
PI3KC3 in complex I and induces autophagy. Autophagosome formation requires the two UBL
conjugation systems. UBL system 1 produces ATG5-ATG12-ATG16 conjugates that attach the
isolation membranes and facilitate membrane nucleation. UBL system 2 modifies LC3 and
incorporates the final product, LC3-II into the autophagosome membrane. The final step in this
process is the fusion of the lysososmes with the autophagosomes, which leads to complete
degradation of autophagosome contents.
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Endoplasmic Reticulum Stress
Proteins that are targeted for the secretory pathway are folded in the lumen of the
endoplasmic reticulum (ER) by chaperones before being transported to the golgi apparatus for
final modification and secretion. If there is an interruption in this process, there is an
accumulation of unfolded proteins in the lumen of the ER that causes stress on the system and is
the trigger for the unfolded protein response (UPR) illustrated in figure 5. The UPR is a series of
actions that collectively reduce the rate of protein synthesis and activates transcription factors
that enhance the function of the ER.92, 93 There are three transmembrane proteins in the
membrane of the ER that sense the accumulation of misfolded proteins and trigger the UPR:
PKR-like eukaryotic initiation factor 2α kinase (PERK), inositol requiring enzyme 1 (IRE1) and
activating transcription factor 6 (ATF6). This sensory mechanism is mediated by the chaperone
protein glucose regulated protein of 78 kDa (GRP78), also known as binding immunoglobulin
protein (BiP), present in the lumen of the ER. Under normal conditions, GRP78 is bound to the
luminal domains of PERK, IRE1 and ATF6, effectively inhibiting their function. When ER stress
occurs, GRP78 is released to bind to the unfolded protein, leading to the activation of the three
stress sensors. Upon activation, ATF6 is proteolytically cleaved and directly translocated into the
nucleus to induce the expression of genes required for the UPR. However, activation of PERK
and IRE1 is associated with the dimerization and subsequent autophosphorylation of specific
residues on their cytoplasmic kinase domains.92, 93 Activated IRE1 induces the formation of the
transcription activator spliced X-box binding protein (XBP1) through splicing of the XBP1
messenger RNA whereas PERK phosphorylates the α subunit of eukaryotic initiation factor 2
(eIF2α). Normally, GTP-bound eIF2α binds to methionyl-transfer RNA and enhances
recognition of the start codon and is released from ribosomal machinery when GTP is
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hydrolyzed. Phosphorylation of the α subunit of eIF2 inhibits the exchange of GDP and GTP;
thus, reducing protein synthesis. Furthermore, activated PERK translationally controls the
expression of activating transcription factor 4 (ATF4) that induces the expression of variable
UPR-related genes involved in amino acid metabolism, regulation of oxidative stress and
apoptosis.93
To prevent aggregation of misfolded proteins in the lumen of the ER during ER stress,
XBP1 and ATF6 increase expression of proteins that facilitate ER-associated degredation
(ERAD). ERAD is accomplished by retrotranslocation of misfolded proteins into the cytosol
followed by ubiquitination and proteasomal degredation. ER stress can also induce autophagy as
an alternate route for protein degredation.92 As previously stated, this process is regulated by
p62, which has the proper domains to bind the ubiquitin moiety of the misfolded proteins as well
as the LC3 on the autophagosomes.88
Severe ER stress can also induce apoptosis by increase the expression of the group III
Bcl-2 family of proteins including Puma, Noxa, BIM and BID which induce the insertion of
proapoptotic proteins Bax and Bak in the mitochondrial membrane, and consequently results in
the release of cytochrome c.92 It has also been suggested that ER stress-induced apoptosis occurs
through cleavage of caspase 4, a member of caspase 1 subfamily that localizes to the ER
membrane.94
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Figure 5: The mechanism of the unfolded protein response.74 Upon accumulation of unfolded
proteins in the lumen of the ER, the chaperone GRP78 (BiP) is released from the luminal
domains of PERK, ATF6 and IRE1. These activated transmembrane proteins then trigger a
cascade of events that collectively result in expression of UPR-related genes. Severe ER stress
can also induce apoptosis through cleavage of ER membrane-bound caspase 4 and inducing
caspase 9.
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Materials and Methods
Materials
For cell culture, RPMI 1640, penicillin/streptomycin, trypsin-EDTA and phosphatebuffered saline solution (PBS) were all purchased from GIBCO (Invitrogen Life Technologies,
Waltham, MA), and the fetal bovine serum was from HyClone Laboratories, Inc. (Thermo
Scientific HyClone, South Logan, UT). Trypan blue solution and dimethyl sulfoxide (DMSO)
were both obtained from Sigma Chemical (St. Louis, MO). The drugs Sildenafil and Celecoxib,
as well as the inhibitor
Recombinant adenoviruses to express constitutively activated c-FLIP-s and Bcl-xL, as
well as dominant negative (DN) caspase 9 and DN AKT were purchased from Vector Biolabs
(Philadelphia, PA). The DNp38 adenovirus was purchased from Cell Biolabs, Inc. (San Diego,
CA). Validated siRNA were all purchased from QIAGEN (Valencia, CA). The opti-MEM
reduced serum medium and the lipofectamine 2000 transfection reagent used for transfections
was purchased from GIBCO (Invitrogen Life Technologies, Waltham, MA).
Antibodies were all purchased from either Cell Signaling Technologies (Worchester,
MA) or Santa Cruz Biotechnology (Santa Cruz, CA) and were diluted 1:1000 in Odyssey infared
imaging system blocking buffer obtained from LI-COR Biosciences (Lincoln, NE). anti-FasL,
anti-CD95, anti- eIF2α, anti-Bcl-xL and anti-GAPDH were all purchased from Santa Cruz
Biotechnology. The anti-ATG5, anti-Beclin 1, anti-ATF4, anti-ATF6, anti-CHOP, anti-caspase
9, anti-FLIP, and anti-p38 (MAPK) were all purchased from Cell Signaling Technologies.
Secondary antibodies used were IRDye 680LT Goat anti-rabbit IgG and IRDye 800CW Goat
anti-mouse IgG, both purchased from LI-COR Biosciences (Lincoln, NE).
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Methods
Cell Culture
BT-474 and BT-549 ductal carcinoma cells were acquired from ATCC (Manassas, VA)
and cultured in RPMI 1640. The medium was supplemented with 10% (v/v) FBS and 100 µg/mL
(1% v/v) penicillin/streptomycin. Cells were maintained in an incubator with 5% CO2 at 37ºC.
Drug Treatments
Plated cells are given a 24 hour period to establish before being treated with indicated
concentrations of Sildenafil and/or Celecoxib. Both drugs were taken from stock solutions and
diluted in DMSO to reach the desired concentrations. In all treatments, the maximal
concentration of solvent did not exceed 0.02% (v/v).
Western Blot Analysis
Cells were plated in 60 x 15 mm dishes and treated with the desired concentration of each
drug for 24 hour. After incubation, cells were lysed and scraped using whole-cell lysis buffer
(0.5 M Tris-HCL, ph 6.8 2% (v/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 0.02%
(v/v) bromophenol blue). Collected samples were boiled for 10 minutes followed by loading onto
8-12% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). Proteins were
electrophretically separated and transferred onto 0.45 µm PVDF membrane using the Bio-Rad
Trans-Blot Turbo system. Membranes were blocked in Odyssey infared imaging system blocking
buffer obtained from LI-COR Biosciences (Lincoln, NE) for an hour. Primary antibody exposure
took place overnight at 4ºC. After washing with TBST, membranes were incubated in the correct
corresponding secondary antibody for a minimum of 1 hour at room temperature. Membranes
were then washed again with TBST before being visualized using the Odyssey Infared Imager
(LI-COR Biosciences, Lincoln, NE).
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Infection with Adenovirus
Cells were plated in 12-well plates and left to establish for 24 hours. Media was removed
and replaced with 1 mL of 5% (v/v) RPMI. Recombinant adenoviruses for caBcl-xL, dnCasp9,
C-FLIP, dnp38, dnAKT and empty vector were added at a multiplicity of infection (MOI) of 50.
Cells were incubated for 24 hours before changing the medium to 10% (v/v) RMPI, followed by
the addition of the indicated concentrations of each drug for 24 hours before being subjected to
trypan blue exclusion assay.
Plasmid and siRNA Transfections
Cells were plated in 12-well plates and left to establish for 24 hours. Media was removed
and replaced with 800 µL of 5% (v/v) RPMI. For transfections, 1 µg of plasmid or 1 µL of
siRNA was added to 100 µL of OPTIMEM per transfection and allowed to incubate for 5
minutes at room temperature. Concurrently, 1 µL of lipofectamine in 100 µL of OPTIMEM per
transfection was also incubated for 5 minutes at room temperature. Both solutions were then
combined and allowed to incubate for 20 minutes at room temperature. After incubation, 200 µL
of the solution was added to the cells, bringing the total volume per well to 1 mL. The plates
were incubated for 24 hours before changing the medium to 10% (v/v) RPMI, followed by the
addition of indicated concentrations of each drug for 24 hours before being subjected to trypan
blue exclusion assay.
Plasmids and siRNA included the scrambled control (SCR), FASL, FADD, ATG5,
Beclin1, ATF4, ATF6, CHOP, eIF2α, dnPERK, and caAKT.
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Trypan Blue Exclusion Assay
The media and any unattached cells from each well of a 12-well plate were transferred to
a 15 mL conical tube. Attached cells were collected via trypsinization with trypsin/EDTA for 2
minutes at 37ºC. After centrifugation at 1,000 rpm for 5 minutes, most of the supernatant was
removed, leaving approximately 50 µL to which 50 µL of trypan blue was added. The pellet was
resuspended in the mixture and counted using a hemocytometer and a light microscope. Cell
death was determined as a percentage of dead cells from the total number of cells counted.
Fluorescence Cell Viability Assay
Cells were plated at a density of 1x104 cells per well on a 96-well plate. After 24 hours
they were drug treated and incubated for an additional 24 hours. A working solution of 2 µM
calcein AM and 4 µM Ethidium homodimer-1 were added to the wells and the plate was
centrifuged at 1,000 rpm for 5 minutes. The plate was then visualized using the Hermes WiScan
(IDEA Bio-Medical LTD Atlanta, GA) to quantify cell death and for imaging.
Colony Formation Assay
Varying numbers of cells were plated on 12-well plates, between 5x102 and 4x103, and
the next day were drug treated with the specified concentration of drugs. The media was then
changed after an additional 24 hours, in which the cells were left to grow. Once the control plate
produces visible, distinct colonies, the media is carefully removed from the wells and is gently
washed with 3 mL of PBS. The PBS is carefully aspirated, and 3 mL of methanol is added to
each well for 10 minutes to fix the cells. The methanol is removed, and the plates are again
washed with 3 mL of PBS. Crystal violet stain is then added for a minimum of 30 minutes. The
stain is removed and the plates are washed with water and left overnight to dry. Upon drying, the
colonies were counted.
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Data Analysis
The effects of the various treatments were analyzed using one-way analysis of variance
and a two-tailed Student’s t-test. Results with a P value of <0.05 were considered statistically
significant.
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Results
The drugs sildenafil (referred to as sil) and celecoxib (referred to as cel) have been
previously used in the context of anticancer therapies. They have been utilized separately, each
to enhance the killing capacity of standard of care treatments already in wide use. Initial
experiments of this study were performed to demonstrate the toxicity of the combination of 2 µM
sildenafil with 10µM celecoxib in both BT 474 and BT 549 cells lines after twenty-four hours of
drug exposure. In each experiment the control group (referred to as vehicle or veh) is treated
with DMSO and serves as a measure of solvent effects for comparison, as the drugs were
dissolved in DMSO for delivery.
The cytotoxic effects of the drugs singularly and in combination were determined by
using the trypan blue exclusion assay, which is considered a measure of cell viability. As seen in
figure 6, sildenafil alone caused a minimal increase in cell death when compared to the vehicle,
yet celecoxib caused an increase in cell death as a singular agent from the vehicle at an average
of 8% to an average of 12% in both cell lines. There was a significant increase in cell death
(P<0.05 compared to vehicle) in the drug combinations of both cell lines, with an even larger
response witnessed in the BT 474 cells at about 22% cell death in comparison to the response
seen in the BT 474 cells at 18%.
It was observed that there was an increase in blebbing and cell debris in treated cells
when compared to control cells, present in both cell lines during their assessments of cell
viability using trypan blue. To better visualize the physical characteristics of cell death,
morphological changes induced by the drugs were characterized by utilizing the fluorescence cell
viability assay. In the BT 474 cells shown in figure 7 and the BT 549 cells in figure 8, there was
an increase in cell death across the treatments, as indicated by the increase in red stained cells.
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Also of note was the decrease in total cells visualized upon treatment, suggesting a potential
cytostatic effect. The combination of 2µM sildenafil and 10 µM celecoxib in the BT 474 cells in
7D illustrated cell elongation and large amounts of cell fragmentation. The BT 549 cells in figure
8D did not illustrate as much cell fragmentation, in agreement with the decreased percentage of
cell death upon comparison with the combination treated BT 474 cells.
For an assessment of a longer term response to the sildenafil and celecoxib combination,
a colony assay was performed to determine long term cell survival following twenty-four hours
of drug treatment. Colony formation illustrates the ability of the cells to survive for a period of
time following exposure to the drugs, with cells that survive the treatment continuing to grow
and produce colonies. As seen in figures 9 and 10, both BT 474 and BT 549 cells responded to
treatment in a similar fashion, with a decrease in cell survival upon increasing concentrations of
both sildenafil and celecoxib, as single agents and in combination. The BT 474 cells illustrated
greater toxicity to both sildenafil and celecoxib overall in comparison to the BT 549 cells; cell
death increased from 24% or 12% with 2 µM sildenafil to 40% or 32% with 10 µM celecoxib,
and the combination of the two caused an even further increase in death to 47% and 36%,
respectively. Taken together with the previous cell death assays performed, this combination of 2
µM sildenafil and 10 µM celecoxib induced a significantly (* P<0.05 compared to vehicle)
increased amount of cell death, working more effectively together than as independent agents.

A
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Figure 6: Assessment of cell viability in BT 474 and BT 549 cells treated with sildenafil and
celecoxib. Cells were treated with DMSO, sildenafil (2µM), celecoxib (10µM) or combination
for 24 hours and then subjected to trypan blue exclusion assay to determine cell viability.
* P<0.05 compared to vehicle.
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Figure 7: Sildenafil and celecoxib cell death visualization in BT 474 cells. BT 474 cells were
treated with DMSO (panel A), sildenafil (2µM, panel B), celecoxib (10µM, panel C) or
combination (panel D). After 24 hours they were visualized using the fluorescence cell viability
assay protocol. Green is indicative of live cells (calcein), while red indicates dead cells
(ethidium).
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Figure 8: Sildenafil and celecoxib cell death visualization in BT 549 cells. BT 549 cells were
treated with control DMSO (panel A), sildenafil (2µM, panel B), celecoxib (10µM, panel C) or
combination (panel D). After 24 hours they were visualized using the fluorescence cell viability
assay protocol. Green is indicative of live cells (calcein), while red indicates dead cells
(ethidium).
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Figure 9: Colony formation assay in BT 474 cells. Cells were treated with indicated µM
concentrations of sildenafil or celecoxib once for a twenty-four hour period and allowed to grow
colonies for seven days before fixing and staining with crystal violet to asses cell survival.
* P<0.05 compared to vehicle. ** P<0.05 comparison between celecoxib at 10 µM and the
combination of 2µM sildenafil and 10 µM celecoxib.
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Figure 10: Colony formation assay in BT 549 cells. Cells were treated with indicated µM
concentrations of sildenafil or celecoxib once for twenty-four hours and allowed to grow
colonies for a week before fixing and staining with crystal violet to asses cell survival.
* P<0.05 compared to vehicle. ** P<0.05 comparison between celecoxib at 10 µM and the
combination of 2µM sildenafil and 10 µM celecoxib.
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Mechanistic Determination of Induced Cell Death
To investigate the mechanism of action of cell death seen in the combination of 2 µM
sildenafil and 10 µM celecoxib, the expression of various proteins involved in the three major
cell death pathways previously mentioned were modulated to assess their involvement in the
sildenafil and celecoxib-mediated cell death observed in both BT 474 and BT 549 cell lines.
For the determination of the possible invovement of apoptosis, some key components of
both the intrinsic and extrinsic pathways were modulated. For intrinsic apoptosis, cells were
infected with adenoviruses carrying an empty vector (CMV) or constructs designed to either upregulate Bcl-xL (caBcl-xL) through consititutive activation or downregulate caspase 9 via
dominant negative mutation (dn Casp9). Cells were infected and then treated with 2µM sildenafil
and/or 10 µM celecoxib for twenty-four hours before they were subjected to trypan blue exlusion
assay to assess cell death. Both cell lines demonstrated a decrease in cell death upon infection of
both intrinsic mediators as seen in figures 11 and 12. The control in both the BT 474 and BT 549
cells illustrated an average of 21% cell death in the combination, while both cell lines produced
an average of 15% cell death in the combination in both caBcl-xL and dnCasp9.
Involvement of the extrinsic aspect of apoptosis was assessed by siRNA mediated
downregulation of FasL and CD95, with a scrambled nonspecific siRNA as control (siSCR), as
well as viral up-regulation of FLIP (c-FLIP). Cells were infected or transfected and then treated
with 2µM sildenafil and/or 10 µM celecoxib for twenty-four hours before they were subjected to
trypan blue exlusion assay to assess cell death. As seen in figures 11, 12 the increase in FLIP
expression caused a decrease in cell death from an average of 21% in the control to 15% in both
BT 474 and BT 549 cells. As illustrated in figure 13, the knockdown of both FasL and CD95
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resulted in decreased cell death. The combination treatment in the siSCR transfected BT 474
cells had cell death averaged at 27% while cell death was measured to be 23% in the BT 549
cells, and both produced significant decreases (* P<0.05 compared to vehicle) in the
combination treatments after the knockdown of both FasL (21% and 19%, respectively) and
CD95 (both 15%).
Cell death through autophagic response was explored by using siRNA downregulation of
ATG5 and Beclin1. Cells were transfected with the SCR control, ATG5 or Beclin1 and then
treated with 2µM sildenafil and/or 10 µM celecoxib for twenty-four hours before they were
subjected to trypan blue exlusion assay to assess cell death. As illustrated in figure 14,
downregulation of ATG5 and Beclin1 decreased cell killing in both BT 474 and BT 549 cells.
The cell death in the siSCR transfected cells upon treatment with the combination was 24% in
both cell lines, yet illustrated slightly different decreases in cell death. There was an overall
decrease in death seen with both ATG5 and Beclin1 knockdown, yet the BT 474 cells produced
17% and 19% changes, respectively, while treatment of the BT 549 cells gave 21% and 17% cell
killing in ATG5 and Beclin1 knockdowns.
For assessing the involvement of the ER stress response, ATF4, ATF6, CHOP and eIF2α
were all downregulated through siRNA-mediated knockdown. Cells were transfected and then
treated with 2µM sildenafil and/or 10 µM celecoxib for twenty-four hours before they were
subjected to trypan blue exlusion assay to assess cell death. In both BT 474 and BT 549 cell
lines, all transfections showed an overall decrease in cell death, as illustrated in figures 15 and
16. The siSCR transfected cells in both cell lines had an average of 20% cell death, with the
combination treatment in every siRNA-mediated knockdown producing a combination cell death
at an average of 15%. Another protein implicated in the ER stress response, p38 MAPK, was
35

investigated through viral infection of the dominant negative mutation of p38 MAPK
(dnp38).This protein is an upstream regulator of CHOP, and was illustrated to have caused a
decrease in cell death, as demonstrated in figures 11 and 12.The CMV infected cells for both BT
474 and BT 549 cell lines upon treatment with the combination had on average 21% cell death,
and the combination treatment in both cell lines upon knockdown of p38 MAPK produced an
average of 15% cell death.
The AKT signaling pathway is implicated in cell proliferation, growth and survival, as
well as regulating apoptosis. Using either plasmid or viral infection, AKT was downregulated
using the dominant negative mutation, and upregulated by mutating it to be constitutively active.
Cells were infected or transfected and then treated with 2µM sildenafil and/or 10 µM celecoxib
for twenty-four hours before they were subjected to trypan blue exlusion assay to assess cell
death. Increasing the expression of AKT caused a protective effect and downregulating it caused
an increase in cell death as seen in figure 17. The control combination treatment in both cell lines
produced cell death of about 18%, with caAKT causing a decrease in death to about 15% and
dnAKT increasing cell death to an average of 27% in both BT 549 and BT 474 cell lines.
All experiments performed illustrated the same characteristic response profile that was
observed in figure 6. It was observed that 2µM sildenafil is seen to have a marginal increase in
cell death that was not significantly different from control, celecoxib as a single agent causes a
significant increase in cell death, with the combination of 2µM sildenafil and 10 µM celecoxib
producing the highest amount of cell death in all experiments, comparatively.
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Figure 11: Viral regulation of Bcl-xL, caspase 9, C-FLIP and p38 downregulated drug
combination-mediated toxicity in BT 474 cells. Cells were first infected with their respective
virus and then treated with vehicle, 2µM sildenafil, 10 µM celecoxib, or combination. Cell
viability was determined by trypan blue exclusion assay 24 hours after treatment. *P <.005 less
than corresponding value of CMV cells.
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Figure 12: Viral regulation of Bcl-xL, caspase 9, C-FLIP and p38 downregulated drug
combination-mediated toxicity in BT 549 cells. Cells were first infected with their respective
virus and then treated with vehicle, 2µM sildenafil, 10 µM celecoxib, or combination. Cell
viability was determined by trypan blue exclusion assay 24 hours after treatment. *P <.005 less
than corresponding value of CMV cells.
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Figure 13: Knockdown of FasL and CD95 reduced drug combination-mediated toxicity.
Cells were first transfected with either siFasL or siCD95 and then treated with vehicle, 2µM
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than
corresponding value of siSCR cells.
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Figure 14: Knockdown of ATG5 and Beclin1 reduced drug combination-mediated toxicity.
Cells were first transfected with siATG5 or siBeclin 1and then treated with vehicle, 2µM
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than
corresponding value of siSCR cells.
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Figure 15: Knockdown of ATF4 and ATF6 reduced drug combination-mediated toxicity.
Cells were first transfected with either siATF4 or siATF6 and then treated with vehicle, 2µM
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than
corresponding value of siSCR cells.
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Figure 16: Knockdown of CHOP and eIF2α reduced drug combination-mediated toxicity.
Cells were first transfected with either siCHOP or sieIF2α and then treated with vehicle, 2µM
sildenafil, 10 µM celecoxib, or combination. Cell viability was determined by trypan blue
exclusion assay 24 hours after treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than
corresponding value of siSCR cells.
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Figure 17: Modulation of AKT casused changes in levels of cell death. Cells were first
infected or transfected and then treated with vehicle, 2µM sildenafil, 10 µM celecoxib, or
combination. Cell viability was determined by trypan blue exclusion assay 24 hours after
treatment, in (A) BT 474 and (B) BT 549 cells. *P <.005 less than corresponding value of siSCR
cells.
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Discussion
Targeted therapies common in treating breast cancer have been generally focused on
hormone and growth receptor pathways, due to the changes in regulation of the receptor
pathways in different types of breast cancers. However, it has been demonstrated that it is
common for resistances to these treatments to form, thus alternative treatment options are
necessary.
Doxorubicin, like many chemotherapeutic agents causes cardiotoxic effects, and upon
supplementation with 10 µM of sildenafil there appeared to be attenuation of this severe side
effect.51 However, upon further investigation sildenafil was shown to enhance cell death by
apoptosis through caspase 9 activity in prostate cancer when paired with doxorubicin treatment.51
It was later demonstrated that sildenafil facilitates cytotoxic chemotherapy killing dependent on
the activation of apoptosis through the extrinsic pathway via death receptors in pediatric CNS
tumors.52
The tumorigenic potential of COX-2 overexpression has frequently been associated with
a resistance to apoptosis, due to the upregulation of AKT signaling.95 It was believed that
celecoxib treatment can inhibit AKT signaling, and thus increase apoptosis through its inhibitory
effects on COX2.61, 96, 97, 98, 99, 100,101 However, a drug called OSU-03012 was developed using
celecoxib as the chemical backbone, yet lacking COX-2 inhibitory activity.100 Cell death upon
treatment with OSU was found to be linked to the AKT pathway, with OSU supressing
phosphorylation of AKT.100 Yet other studies have shown that the toxicity produced by OSU was
not closely correlated with the suppression of AKT signaling, indicating other methods of killing
may be involved.102 It was later elucidated that both autophagy and ER stress played a role in
OSU lethality, with knockdown of ATG5 and Beclin1 suppressing cell killing as well as the
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supression of BiP, that causes a PERK-dependent autophagic response.103, 104 This demonstrated
that celecoxib may be killing through apoptosis via the AKT pathway since it is indicated both in
cells treated with celecoxib as well as OSU, yet also regulating autophagy and ER stress in a
COX-independent manner.
Further studies demonstrated that the intrinsic pathway is involved in cell death upon
treatment with celecoxib.105 It has been observed that there is a decrease in expression of
antiapoptotic proteins such as Bcl-2 and Bcl-xL, and expression of the proapoptotic protein Bad
increases upon treatment, causing the release of cytochrome c from the mitochondria and
inducing caspases 3, 8, and 9.105, 106, 107, 108The extrinsic pathway was noted to be activated as
well, through FasL and CD95signaling in celecoxib treated cervical carcinoma cells.109, 110, 111
Celecoxib treatment also increases ceramide levels in mammary tumor cells, and increases in
ceramide levels are associated with the induction of apotosis.112, 113, 114, 115 It has been shown that
ceramide is important for the generation of receptor clusters, including CD95 clustering, and it
constitutes an important prerequisite for receptor signaling.116
Results of the studies performed in this manuscript indicated that 2 µM sildenafil and 10
µM celecoxib worked better in combination than individually to promote cell killing in both BT
474 and BT 549 breast cancer cell lines, with a higher toxicity illustrated in BT 474 cells (figures
6-10). Through various modulations of key players in cell death pathways, it is suggested that the
extrinsic, receptor-mediated pathway of apoptosis may be the major effector of cell death in this
drug combination. The downregulation of FasL and CD95 in figure 13 illustrates the production
of a larger protective effect from cell death when compared to other knockdowns. The overexpression of FLIP, an inhibitor that blocks the activation of caspase 8, also shows a protective
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effect (figure 11), further indicating the role of the extrinsic apoptotic pathway in cell death via
the combination of 2 µM sildenafil and 10 µM celecoxib.
There was a less pronounced change in cell death present through the changes in
autophagy and ER stress, yet the downregulation of proteins involved in these pathways
suggested that they too are playing a role in cell death mediated by the drug combination of
sildenafil and celecoxib. The decrease in cell death seen after knockdown of ATG5 and Beclin1
in figure 14 coincides with the literature produced on OSU, as well as the results on the induction
of ER stress. While PERK itself was not used in these experiments, the protective effects of
siRNA-mediated knockdown of eIF2α, a down stream target of PERK, and ATF4 (figures 15
and 16) which is acted on by eIF2α may implicate a dependence on PERK signaling in the ER
stress response as well as the induction of ATF6 and p38 MAPK to act on CHOP. Modulation of
AKT signaling also followed what is expected of celecoxib treatment, in that further reduction in
AKT signaling through dominant negative downregulation increased cell death, while increasing
its activation decreased cell killing.
It is commonly seen in the literature that these drugs are used at non-clinically relevant
doses, such as 10µM sildenafil and 50 µM celecoxib.51, 60, 100 The concentrations used in these
experiments are within the clinically acheiveable range, and still induced cell death. This was
further verified by unpublished data that has since been produced in the lab, when 2µM silenafil
and 10µM celecoxib was used in vivo and the combination was successful in slowing the
progresssion of tumor growth in athymic nude mice. Our lab has also recently produced results
that indicated the combination of 2µM sildenafil and 10 µM celecoxib is capable of killing in a
number of other cancers, including brain and colon. Ceramide assays have also been performed,
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and results indicate that ceramide levels do indeed increase with celecoxib treatment as expected,
and the effect is even further enhanced when sildenafil is added to the treatment in combination.
Taken together, the results presented in this manuscript agree with the literature on the
potential mechanisms of cell death induced by celecoxib, and indicates that the addition of 2 µM
sildenafil upon treatment with 10 µM celecoxib enhances toxicity through the induction of ER
stress, autophagy, and both apoptotic pathways, with a larger emphasis on the extrinsic pathway.
It is a novel combination with a multi-pronged approach to the treatment of breast cancer
specifically, with implications for future work in multiple types of cancer.
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